850 related articles for article (PubMed ID: 26155413)
1. Are BiTEs the "missing link" in cancer therapy?
Suryadevara CM; Gedeon PC; Sanchez-Perez L; Verla T; Alvarez-Breckenridge C; Choi BD; Fecci PE; Sampson JH
Oncoimmunology; 2015 Jun; 4(6):e1008339. PubMed ID: 26155413
[TBL] [Abstract][Full Text] [Related]
2. A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model.
Meckler JF; Levis DJ; Vang DP; Tuscano JM
Cancer Immunol Immunother; 2023 Sep; 72(9):2939-2948. PubMed ID: 37247022
[TBL] [Abstract][Full Text] [Related]
3. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
[TBL] [Abstract][Full Text] [Related]
4. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibodies in haematological malignancies.
Viardot A; Bargou R
Cancer Treat Rev; 2018 Apr; 65():87-95. PubMed ID: 29635163
[TBL] [Abstract][Full Text] [Related]
6. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer.
Zarrabi KK; Narayan V; Mille PJ; Zibelman MR; Miron B; Bashir B; Kelly WK
Ther Adv Urol; 2023; 15():17562872231182219. PubMed ID: 37359737
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
8. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.
Stieglmaier J; Benjamin J; Nagorsen D
Expert Opin Biol Ther; 2015; 15(8):1093-9. PubMed ID: 25971805
[TBL] [Abstract][Full Text] [Related]
9. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.
Tian Z; Liu M; Zhang Y; Wang X
J Hematol Oncol; 2021 May; 14(1):75. PubMed ID: 33941237
[TBL] [Abstract][Full Text] [Related]
10. The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types.
Einsele H; Borghaei H; Orlowski RZ; Subklewe M; Roboz GJ; Zugmaier G; Kufer P; Iskander K; Kantarjian HM
Cancer; 2020 Jul; 126(14):3192-3201. PubMed ID: 32401342
[TBL] [Abstract][Full Text] [Related]
11. T cell-engaging therapies - BiTEs and beyond.
Goebeler ME; Bargou RC
Nat Rev Clin Oncol; 2020 Jul; 17(7):418-434. PubMed ID: 32242094
[TBL] [Abstract][Full Text] [Related]
12. [Cancer therapy using bispecific antibodies].
Kadowaki N
Rinsho Ketsueki; 2018; 59(10):1942-1947. PubMed ID: 30305495
[TBL] [Abstract][Full Text] [Related]
13. Redirecting T cells to hematological malignancies with bispecific antibodies.
Velasquez MP; Bonifant CL; Gottschalk S
Blood; 2018 Jan; 131(1):30-38. PubMed ID: 29118005
[TBL] [Abstract][Full Text] [Related]
14. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
Goebeler ME; Bargou R
Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
[TBL] [Abstract][Full Text] [Related]
15. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
Fournier P; Schirrmacher V
BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
[TBL] [Abstract][Full Text] [Related]
16. Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors.
Yin Y; Rodriguez JL; Li N; Thokala R; Nasrallah MP; Hu L; Zhang L; Zhang JV; Logun MT; Kainth D; Haddad L; Zhao Y; Wu T; Johns EX; Long Y; Liang H; Qi J; Zhang X; Binder ZA; Lin Z; O'Rourke DM
Mol Ther; 2022 Jul; 30(7):2537-2553. PubMed ID: 35570396
[TBL] [Abstract][Full Text] [Related]
17. T-Cell Engagers-The Structure and Functional Principle and Application in Hematological Malignancies.
Cech P; Skórka K; Dziki L; Giannopoulos K
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672662
[TBL] [Abstract][Full Text] [Related]
18. Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement.
Long M; Mims AS; Li Z
Immunol Invest; 2022 Nov; 51(8):2176-2214. PubMed ID: 36259611
[TBL] [Abstract][Full Text] [Related]
19. Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells.
Urbanska K; Lynn RC; Stashwick C; Thakur A; Lum LG; Powell DJ
J Transl Med; 2014 Dec; 12():347. PubMed ID: 25496493
[TBL] [Abstract][Full Text] [Related]
20. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]